Trial Profile
An Open Label Phase II Clinical Study to Evaluate the Safety and Pharmacokinetics of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous (AML) and Lymphoblastic Leukaemia (ALL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Amphotericin B (Primary)
- Indications Mycoses
- Focus Adverse reactions; Registrational
- Sponsors Matinas BioPharma
- 06 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jan 2019 Planned End Date changed from 1 Apr 2020 to 1 Dec 2020.
- 04 Jan 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Dec 2020.